Medications affecting the IGF-1/Growth Hormone Axis, including teprotumumab, somatostatin analogues and anti-CGRP monoclonal antibodies, are associated with an elevated reporting odds of alopecia in women; a pharmacovigilance study - SUPPLEMENTAL MATERIAL

Published: 11 April 2023| Version 1 | DOI: 10.17632/tpgy3dwkf5.1
Contributor:

Description

Supplemental data for publication: Medications affecting the IGF-1/Growth Hormone Axis, including teprotumumab, somatostatin analogues and anti-CGRP monoclonal antibodies, are associated with an elevated reporting odds of alopecia in women; a pharmacovigilance study

Files

Institutions

University of Arizona

Categories

Publication

Licence